Purpose: To determine the safety, tolerability, and efficacy of human recombinant decorin
protein, a transforming growth factor ß (TGFß) inhibitor in preventing proliferative
vitreoretinopathy (PVR) in patients with perforating globe injuries.
Methods: This is a prospective, single-center, open-label, interventional case series. A
single intravitreal injection of decorin 200ug (n=4) and 400ug (n=8) was given within 24
hours of injury. Pars plana vitrectomy with silicone oil injection was done if indicated. ERG
was done before injections, at day 10, and 3 months. Serial plasma decorin levels were
assessed before injections, day 3, 5, and 10 post-injection. Clinical assessment included
globe survival, retinal attachment rate, and PVR evaluation.